Reuters logo
4 months ago
BRIEF-Asit Biotech announces that it has achieved primary endpoint of phase I/IIa clinical trial with its hdm-ASIT+ product candidate for house dust mite rhinitis
April 4, 2017 / 4:47 PM / 4 months ago

BRIEF-Asit Biotech announces that it has achieved primary endpoint of phase I/IIa clinical trial with its hdm-ASIT+ product candidate for house dust mite rhinitis

1 Min Read

April 4 (Reuters) - Asit Biotech SA:

* Announces that it has achieved the primary endpoint of the phase I/IIa clinical trial with its hdm-ASIT+ product candidate for house dust mite rhinitis

* Confirmation of hdm-ASIT+'s safety and tolerability profile

* Conjunctival provocation test showed a slight numerical difference in favour of treated group compared to placebo group (not statistically significant) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below